- Page 1 and 2:
Alaska Tuberculosis Program Manual
- Page 3 and 4:
Purpose............................
- Page 5 and 6:
Monthly assessment of adherence ...
- Page 7 and 8:
When to Expand a Contact Investigat
- Page 9 and 10:
Introduction CONTENTS About the Ala
- Page 11 and 12:
How to Use This Manual Portable Doc
- Page 13 and 14:
Printing To access the print dialog
- Page 15 and 16:
Abbreviations Refer to the list bel
- Page 17 and 18:
QFT QuantiFERON ® -TB test QFT-G Q
- Page 19 and 20:
Alaska Statutes and Regulations on
- Page 21 and 22:
National and State Program Objectiv
- Page 23 and 24:
Indicator 3 Thorough contact invest
- Page 25 and 26:
National Standards and Recommendati
- Page 27 and 28:
Roles and Responsibilities Contact
- Page 29 and 30:
Local Public Health Agencies Table
- Page 31 and 32:
Resources and References Resources
- Page 33 and 34:
Introduction Purpose Use this secti
- Page 35 and 36:
Contact investigation: Collecting,
- Page 37 and 38:
Reporting Tuberculosis Detecting an
- Page 39 and 40:
Prompt reporting (prior to culture
- Page 41 and 42:
Use the Infectious Disease Report F
- Page 43 and 44:
Data Collection Forms The following
- Page 45 and 46:
Genotyping Genotyping is a useful t
- Page 47 and 48:
References 1 ATS, CDC, IDSA. Contro
- Page 49 and 50:
Introduction Purpose Use this secti
- Page 51 and 52:
child or a person acting on behalf
- Page 53 and 54:
When to Conduct Targeted Testing Al
- Page 55 and 56:
Alaska Program Standards for Health
- Page 57 and 58:
B Notifications CONTENTS Introducti
- Page 59 and 60:
Table 1: NUMBERS OF FOREIGN-BORN PE
- Page 61 and 62:
chest radiograph and if sputum AFB
- Page 63 and 64:
Follow-up of B1 and B2 Tuberculosis
- Page 65 and 66:
Evaluation of B1, B2, and B Tubercu
- Page 67 and 68:
Treatment Prescribe medications as
- Page 69 and 70:
12 Centers for Disease Control and
- Page 71 and 72:
Introduction Purpose Use this secti
- Page 73 and 74:
Tuberculosis Classification System
- Page 75 and 76:
Table 2: PERSONS AT HIGH RISK FOR T
- Page 77 and 78:
Table 3: WHEN TO SUSPECT PULMONARY
- Page 79 and 80:
Diagnosis of Tuberculosis Disease T
- Page 81 and 82:
1. Exposure to Infectious TB: Ask p
- Page 83 and 84:
Physical Examination A physical exa
- Page 85 and 86:
For more information on chest radio
- Page 87 and 88:
Laboratories should report positive
- Page 89 and 90:
Guidelines for preventing the trans
- Page 91 and 92:
50 CDC. National plan for reliable
- Page 93 and 94:
Introduction Purpose The overall go
- Page 95 and 96:
Basic Treatment Principles Follow t
- Page 97 and 98:
Treatment Regimens and Dosages Use
- Page 99 and 100: Table 3: FOUR TREATMENT REGIMENS FO
- Page 101 and 102: † 4 Table 4: DOSES*OF FIRST-LINE
- Page 103 and 104: Figure 1:TREATMENT ALGORITHM FOR DR
- Page 105 and 106: a. In remote locations in Alaska, m
- Page 107 and 108: Antituberculosis Drug Rifampin (RIF
- Page 109 and 110: Antituberculosis Drug Rifapentine (
- Page 111 and 112: Reporting Reactions The table below
- Page 113 and 114: Response to Treatment For consultat
- Page 115 and 116: Figure 2: MANAGEMENT OF TREATMENT I
- Page 117 and 118: Post-Treatment Evaluation Routine f
- Page 119 and 120: Treatment in Special Situations Tre
- Page 121 and 122: Resources For consultation regardin
- Page 123 and 124: with an increase in overall complet
- Page 125 and 126: Liver Disease Management of TB in p
- Page 127 and 128: After the initial phase (first two
- Page 129 and 130: Extrapulmonary Tuberculosis The bas
- Page 131 and 132: Resources and References Resources
- Page 133 and 134: Diagnosis of Latent Tuberculosis In
- Page 135 and 136: Forms All required and recommended
- Page 137 and 138: High-Risk Groups Certain factors id
- Page 139 and 140: Diagnosis of Latent Tuberculosis In
- Page 141 and 142: continually exposed to populations
- Page 143 and 144: Administration of the Tuberculin Sk
- Page 145 and 146: See “Two-Step Tuberculin Skin Tes
- Page 147 and 148: See “Live-Virus Vaccines” under
- Page 149: For more information on IGRAs and t
- Page 153 and 154: Resources and References Resources
- Page 155 and 156: Treatment of Latent Tuberculosis In
- Page 157 and 158: Policy Detailed information on the
- Page 159 and 160: Window period prophylaxis is treatm
- Page 161 and 162: Regimens Identify an appropriate re
- Page 163 and 164: Dosages Once the appropriate regime
- Page 165 and 166: Side Effects and Adverse Reactions
- Page 167 and 168: If a patient reports to a healthcar
- Page 169 and 170: Antituberculosis Drug Rifampin (RIF
- Page 171 and 172: DOT is strongly encouraged for thos
- Page 173 and 174: Table 7 describes the duration of t
- Page 175 and 176: Alcoholism Alcohol-Related Treatmen
- Page 177 and 178: Medication Administration and Pharm
- Page 179 and 180: National Tuberculosis Controllers A
- Page 181 and 182: 24 CDC . “Recommendations for Use
- Page 183 and 184: Diagnosis and Treatment of Latent T
- Page 185 and 186: All children suspected or diagnosed
- Page 187 and 188: Latent Tuberculosis Infection (LTBI
- Page 189 and 190: History of BCG vaccination is not a
- Page 191 and 192: Because of their higher specificity
- Page 193 and 194: Table 3: COUNTRIES AND AREAS WITH A
- Page 195 and 196: Treatment of Latent TB Infection (L
- Page 197 and 198: For consultation regarding the trea
- Page 199 and 200: Monitoring DOT is mandatory for INH
- Page 201 and 202:
For young infants, some experts rec
- Page 203 and 204:
TABLE 8: SIGNS AND SYMPTOMS OF PULM
- Page 205 and 206:
Treatment of Tuberculosis Basic pri
- Page 207 and 208:
Regime n 1 2 3 ❺ Table 10: FOUR T
- Page 209 and 210:
† 35 Table 11: DOSES*OF FIRST-LIN
- Page 211 and 212:
Monitoring Response to Treatment Ch
- Page 213 and 214:
Child Care and Schools: Children wi
- Page 215 and 216:
Other TB medications are not commer
- Page 217 and 218:
10 Centers for Disease Control and
- Page 219 and 220:
Case Management CONTENTS Introducti
- Page 221 and 222:
patient-centered approach to case m
- Page 223 and 224:
Alaska TB Program: Timeline for the
- Page 225 and 226:
For assistance with language issues
- Page 227 and 228:
Ascertain the extent of TB illness
- Page 229 and 230:
medical/health problem. The date of
- Page 231 and 232:
necessary to teach people how to ta
- Page 233 and 234:
Treatment Plan Components Recommend
- Page 235 and 236:
Implementation Activities To begin
- Page 237 and 238:
o Indicate the number of doses prov
- Page 239 and 240:
Review the status of the contact in
- Page 241 and 242:
For more information, see the “Di
- Page 243 and 244:
importance of continued treatment a
- Page 245 and 246:
5. Review information with the prov
- Page 247 and 248:
Completion of Therapy The case mana
- Page 249 and 250:
Case Closures Other than Completion
- Page 251 and 252:
Conduct a case management meeting o
- Page 253 and 254:
Biweekly (BIW) doses of TB medicati
- Page 255 and 256:
Use DOT with other measures such as
- Page 257 and 258:
It is important not to send a mixed
- Page 259 and 260:
Medical Orders Progressive Interven
- Page 261 and 262:
CDC. Module 9: “Patient Adherence
- Page 263 and 264:
36 New Jersey Medical School Nation
- Page 265 and 266:
75 CDC. Module 9: patient adherence
- Page 267 and 268:
Introduction Purpose A contact inve
- Page 269 and 270:
For roles and responsibilities, ref
- Page 271 and 272:
Decision to Initiate a Contact Inve
- Page 273 and 274:
chest radiographic findings that ar
- Page 275 and 276:
In general, a contact investigation
- Page 277 and 278:
Time Frames for Contact Investigati
- Page 279 and 280:
Circumstances unique to Alaska may
- Page 281 and 282:
Circumstances unique to Alaska may
- Page 283 and 284:
Activity Purpose Maximum Time Inter
- Page 285 and 286:
Infectious Period Determine the inf
- Page 287 and 288:
In general, for the purposes of con
- Page 289 and 290:
General Guidelines for Interviewing
- Page 291 and 292:
Healthcare workers should remember
- Page 293 and 294:
Index Patient with Positive Acid-Fa
- Page 295 and 296:
Index Patient with Negative Acid-Fa
- Page 297 and 298:
Contact Evaluation, Treatment, and
- Page 299 and 300:
Definition of abbreviations: HIV =
- Page 301 and 302:
Note: An IGRA may be used in place
- Page 303 and 304:
When to Expand a Contact Investigat
- Page 305 and 306:
Figure 7: EVALUATION, TREATMENT, AN
- Page 307 and 308:
CDC’s “Framework of Program Eva
- Page 309 and 310:
Definitions of abbreviations: AIDS
- Page 311 and 312:
elease assay; LTBI = latent tubercu
- Page 313 and 314:
officials to distinguish between di
- Page 315 and 316:
References 1 ATS, CDC, IDSA. Contro
- Page 317 and 318:
44 CDC, NTCA. Guidelines for the in
- Page 319 and 320:
Introduction Purpose Use this secti
- Page 321 and 322:
Available Laboratory Tests Table 2:
- Page 323 and 324:
Table 3: PCR Testing Algorithm and
- Page 325 and 326:
Table 4: SPECIMEN COLLECTION METHOD
- Page 327 and 328:
5. If possible, send the specimen o
- Page 329 and 330:
Specimen Shipment There are three m
- Page 331 and 332:
Resources and References Resources
- Page 333 and 334:
Patient Education CONTENTS Introduc
- Page 335 and 336:
treatment, common side-effects of m
- Page 337 and 338:
Education Topics During the initial
- Page 339 and 340:
10. Explain the signs and symptoms
- Page 341 and 342:
Patient Education Materials Get th
- Page 343 and 344:
References 1 CDC. Module 4: treatme
- Page 345 and 346:
Introduction Purpose Use this secti
- Page 347 and 348:
National Guidelines The following g
- Page 349 and 350:
Transfer Notifications CONTENTS Int
- Page 351 and 352:
For roles and responsibilities, ref
- Page 353 and 354:
Follow-Up Type When to Initiate Not
- Page 355 and 356:
Action Transfers Within Alaska Tran
- Page 357 and 358:
Provide the patient with a. A copy
- Page 359 and 360:
References 1 CDC. International not
- Page 361 and 362:
Infection Control CONTENTS Introduc
- Page 363 and 364:
of TB infection control principles
- Page 365 and 366:
Administrative Activities 13 Key ac
- Page 367 and 368:
Personal Respiratory Protection Alt
- Page 369 and 370:
For regulations in your area, refer
- Page 371 and 372:
Employee Health All employees, phys
- Page 373 and 374:
Figure 1: TWO STEP TESTING AND FOLL
- Page 375 and 376:
Isolation To reduce disease transmi
- Page 377 and 378:
Table 4: CRITERIA FOR PATIENTS TO B
- Page 379 and 380:
When to Initiate Airborne Infection
- Page 381 and 382:
Confirmed Tuberculosis Disease A pa
- Page 383 and 384:
Multidrug-Resistant Tuberculosis Di
- Page 385 and 386:
Environmental Controls in the Patie
- Page 387 and 388:
Return to Work, School, or Other So
- Page 389 and 390:
Tuberculosis Infection Control in P
- Page 391 and 392:
Transportation Vehicles To prevent
- Page 393 and 394:
7 CDC. Guidelines for preventing th
- Page 395 and 396:
Forms: Alaska State Public Health L
- Page 397 and 398:
ALASKA STATE PUBLIC HEALTH LABORATO
- Page 399 and 400:
Anchorage Alaska State Public Healt
- Page 401 and 402:
INDEX CASE INFORMATION Name: DOB: /
- Page 403 and 404:
CONTACT Name: Tuberculosis Contact
- Page 405 and 406:
Directly Observed Therapy (DOT) Cal
- Page 407 and 408:
B. Documents patient care activitie
- Page 409 and 410:
Alaska TB Program Section of Epidem
- Page 411 and 412:
Treatment Summary for Active TB Nam
- Page 413 and 414:
Interjurisdictional Tuberculosis No
- Page 415 and 416:
! !"#$%&'%()*(+#(,"-./0'1$%+'.,)()/
- Page 417 and 418:
! B!9:(78;7)3702D!! ! 3"#$%&%''98#5
- Page 419 and 420:
! ?"#51)09/02!H0/.!9:(78;7)37028!/'
- Page 421 and 422:
Latent Tuberculosis Infection (LTBI
- Page 423 and 424:
Alaska Tuberculosis Program 9210 Va
- Page 425 and 426:
Instructions for Collecting Sputum
- Page 427 and 428:
TB Case Management Information Requ
- Page 429 and 430:
Table 1: First-line anti-tuberculos
- Page 431 and 432:
Return the fax to the Drug Room (90
- Page 433 and 434:
Stock Orders: A small supply of
- Page 435 and 436:
TB/LTBI Medication Return Form Reas
- Page 437 and 438:
TB/LTBI Stock Medication Request FA
- Page 439 and 440:
TB Medication Dose Monitoring Regim
- Page 441 and 442:
TB Medication Dose Monitoring Regim
- Page 443 and 444:
ALASKA DEPARTMENT OF HEALTH AND SOC
- Page 445:
Tuberculosis Discharge Planning Che
- Page 448 and 449:
PART 2: 8. Have you ever been told
- Page 450 and 451:
Tuberculosis Treatment Contract Dep
- Page 452 and 453:
Statutes and Regulations Contents I
- Page 454 and 455:
Regulations Infection Control 7 AAC
- Page 456 and 457:
place of work is remote from patien
- Page 458 and 459:
(2) the child or a person acting on
- Page 460 and 461:
Glossary acid-fast bacilli (AFB): M
- Page 462 and 463:
eaction size on a later test, which
- Page 464 and 465:
disseminated TB: See miliary TB. dr
- Page 466 and 467:
immunocompromised and immunosuppres
- Page 468 and 469:
include medical history and TB symp
- Page 470 and 471:
thousands to millions of copies of
- Page 472 and 473:
secondary (TB) case: A new case of
- Page 474:
eproducing TB organisms from respir